|
|
|
|
Science Sparks @ ACTREC
|
 18 September 2023 |
Vol. No. 12; Issue No. 596 |
|
|
Publications
|
|
1. Ravichandran G, Harijan D, Ganapathy N, Prabusankar G, De A, Rengan K (2023). The multifaceted role of degradable cobalt nanoparticles: Dual-target starvation and intracellular acidification engendering LC3-associated whole-cell autophagy. ACS Materials Letters.
2. Grover S, Lichter K, Likhacheva A, Jang J, Ning M, Robin T, Small W, Kudchadker R, Swamidas J, Chopra S, Rai B, Dutt Sharma S, Sharma D, Kuppusamy T, Yang R, Berger D, Mendez L, Glaser S, Erickson D, Chino J, Mourtada F, Abdel-Wahab M, Jhingran A, Simonds H, Mahantshetty U (2023). The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries. Brachytherapy.
3. Mahantshetty U, Kashid S, Mulye G, Gurram L, Engineer R, Chopra S, Ghosh J, Gulia S, Gupta S, Ghadi Y, Dheera A, Kohle S, Kadam S, Menon S, Deodhar K, Maheshwari A, Shylasree TS, Lewis S, Kalyani N, Shrivastava SK (2023). Reirradiation with advanced brachytherapy techniques in recurrent GYN cancers. Brachytherapy.
4. Chatterjee G, Dhende P, Raj S, Shetty V, Ghogale S, Deshpande N, Girase K, Patil J, Kalra A, Narula G, Dalvi K, Dhamne C, Moulik NR, Rajpal S, Patkar NV, Banavali S, Gujral S, Subramanian PG, Tembhare PR (2023). 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges. European Journal of Haematology.
Thesis
Saim Wasi Mulla. 2023. Proteasomal Chaperones and the Cross-Talk with NF-κB Signaling- An Integrated Network and Experimental approach. (LIFE09201404010) (Guide: Dr. Prasanna Venkatraman)
|
|
|
|
|
Interesting Reads
|
|
Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, Li X, Shen G, Peng J, Zheng P, Gu Y, Chen J, Lin M, Deng C, Gao H, Lu Z, Zhao Y, Luo M. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023
|
|
|
Video of the Week
|
|
| Changing Epidemiology of Hepatocellular Carcinoma |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2018, Cemiplimab (Libtayo) became the first approved therapy for patients with advanced cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer.
|
|
|
|
|
|
2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
